Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
COCP
Cocrystal Pharma Inc
3.15
0.10 (3.28%)
Volume: 92,238
Day Range: 3.00 - 3.17
Last Trade Time: 7:59:46 PM EST
Good to see another one in our Jan effect is paying off COCP under 1.80 now its 2.80 in less than 30 days. We might hold half the position after today we will see what the market has to offer today. Lets see if volume comes in. Have a great day and keep the winners as long as one can.
COCP
Cocrystal Pharma Inc
2.36
-0.02 (-0.84%)
Volume: 14,346
Day Range: 2.30 - 2.44
Last Trade Time: 6:46:08 PM EST
COCP
Cocrystal Pharma Inc
2.36
-0.02 (-0.84%)
Volume: 14,346
Day Range: 2.30 - 2.44
Last Trade Time: 6:46:08 PM EST
COCP
Cocrystal Pharma Inc
2.23
-0.07 (-3.04%)
Volume: 56,339
Day Range: 2.14 - 2.35
Bid: 1.75
Ask: 2.78
Last Trade Time: 6:27:18 PM EDT
Total Trades: 1,535
COCP Detailed Quote
COCP
Cocrystal Pharma Inc
0.4074
-0.0085 (-2.04%)
Volume: 168,436
Day Range: 0.395 - 0.4199
Bid: 0.40
Ask: 0.4074
Last Trade Time: 4:54:06 PM EDT
Total Trades: 286
COCP Detailed Quote
COCP
Cocrystal Pharma Inc
0.4324
0.0295 (7.32%)
Volume: 100,459
Day Range: 0.40 - 0.4389
Bid: 0.4104
Ask: 0.44
Last Trade Time: 4:36:29 PM EDT
Total Trades: 372
COCP Detailed Quote
Cocrystal Pharma Inc (COCP)
0.437 ? -0.001 (-0.23%)
Volume: 108,757 @06/03/22 7:10:18 PM EDT
Bid Ask Day's Range
0.4251 0.44 0.42 - 0.44
COCP Detailed Quote
Cocrystal Pharma Inc (COCP)
0.47 ? -0.0022 (-0.47%)
Volume: 240,519 @04/29/22 4:08:39 PM EDT
Bid Ask Day's Range
0.4505 0.47 0.45 - 0.4822
COCP Detailed Quote
Mini base formed.......75/85 target.
Cocrystal Pharma Inc (COCP)
0.51 ? 0.0002 (0.04%)
Volume: 225,331 @03/11/22 5:45:15 PM EST
Bid Ask Day's Range
0.4903 0.51 0.49 - 0.52
COCP Detailed Quote
What a mistake, thought I was done with dogs.
Cocrystal Pharma Inc (COCP)
0.56 ? 0.0195 (3.61%)
Volume: 121,738 @02/04/22 6:06:17 PM EST
Bid Ask Day's Range
0.545 2.91 0.541 - 0.57
COCP Detailed Quote
CC-42344 Phase 1 Safety and PK Study in Healthy Participants - NCT05202379
https://newsfilter.io/a/0074b5e846d912df287f0250bb498fda
Not sure where the bottom is here, but antivirals are poised for a huge comeback this year imo with the APP program. Cocrystal is in a great position to be a part of that, sky is the limit imho
https://ir.cocrystalpharma.com/ir-calendar
H.C. Wainwright BioConnect Virtual Conference
JAN 10, 2022 • 7:00 AM
Overall market conditions keeping this down, has been nothing but good news for COCP
Been considering a position here but since I started watching it its been nothing but down, what the story??
COCP here we go 3x position completed
best things take time
Tomorrow the day to buy, everyone selling for loss.
BOTH POSSIBLE, CEO SEEMS TO BE ON TARGET. NEEDS MORE DATA $COCP
YES YES YES $COCP WAKEUP Cocrystal Pharma with a $4.50 average price target, which is a 442.
https://www.tipranks.com/news/blurbs/cocrystal-pharma-cocp-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Cocrystal Pharma (COCP) Receives a Buy from H.C. Wainwright
November 29 2021 - 06:17AM
TipRanks
Alert
Print
Share On Facebook
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report) today and set a price target of $4.00. The company's shares closed last Friday at $0.98, close to its 52-week low of $0.79. According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.3% and a 24.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as NeuroBo Pharmaceuticals, Oncternal Therapeutics, and Aquestive Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cocrystal Pharma with a $4.50 average price target, which is a 442.
https://www.tipranks.com/news/blurbs/cocrystal-pharma-cocp-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Cocrystal Pharma Inc (COCP)
0.872 ? -0.0979 (-10.09%)
Volume: 2,203,440 @11/29/21 7:40:56 PM EST
Bid Ask Day's Range
0.856 0.87 0.85 - 0.9714
COCP Detailed Quote
Cocrystal Pharma Inc (COCP)
0.95 ? -0.0299 (-3.05%)
Volume: 496,138 @11/05/21 7:40:25 PM EDT
Bid Ask Day's Range
0.9401 0.95 0.9255 - 0.98
COCP Detailed Quote
COCP
Bid: 0.95 Ask: 0.96 Last: 0.955 Chg ($): 0.005 Vol: 526.40K
in incubation period
$COCP Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
Cocrystal Pharma, Inc.
Wed, October 6, 2021, 5:49 AM
https://finance.yahoo.com/news/cocrystal-pharma-receives-australian-regulatory-124900491.html
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE)
-- Cocrystal Pharma, Inc. (Nasdaq: COCP)
(“Cocrystal” or the “Company”), a clinical-stage biotechnology
company discovering and developing novel antiviral therapeutics
that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces receipt of clearance
from an Australian Human Research Ethics Committee (HREC) to initiate
a Phase 1 trial with its orally administered PB2 inhibitor CC-42344
for the treatment of pandemic and seasonal influenza A.
The Phase 1 randomized, double-blind, placebo-controlled study is expected to enroll 56 healthy volunteers at a single site in Australia. The study is designed to assess the safety, tolerability and pharmacokinetics of CC-42344.
CC-42344 binds to a highly conserved PB2 site of influenza
polymerase complex and exhibits a novel mechanism of action that inhibits viral replication.
In preclinical testing, CC-42344 demonstrated excellent antiviral activity against influenza A strains, including avian pandemic
strains and Tamiflu® and Xofluza®-resistant strains, as well as favorable pharmacokinetic and drug-resistance profiles.
“The need for a novel, broad-spectrum, oral antiviral for pandemic
and seasonal influenza A is clear as current approved influenza treatments are partially effective and are prone to viral resistance,” said Sam Lee, Ph.D.,
Cocrystal’s President and co-interim CEO.
“We discovered CC-43244 using our proprietary structure-based drug discovery platform technologies.
CC-43244 is specifically designed
to be effective against pandemic and seasonal influenza A strains
and emerging avian influenza viruses.”
“Our decision to conduct the Phase 1 trial in Australia was due to favorable regulatory policies
and a clinical trial environment that aligns with our strategy for rapid, cost-efficient
and high-quality clinical development,” added James Martin,
Cocrystal’s CFO and co-interim CEO.
“We are delighted to begin our first clinical study with CC-42344 as a treatment for this major global health concern.”
The World Health Organization (WHO) estimate there are approximately
1 billion cases of influenza annually worldwide,
resulting in 3 million to 5 million cases of severe illness
and 290,000 to 650,000 deaths. The Center for Disease Control (CDC) estimates that since 2010 influenza has resulted in 9 million to 45 million illnesses in the U.S. annually,
resulting in 140,000 to 810,000 hospitalizations and 12,000 to 61,000 deaths.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target
the replication process of coronaviruses (including SARS-CoV-2), influenza viruses,
hepatitis C virus and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit http://www.cocrystalpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding conducting the Phase 1 study of CC-42344 in Australia and our strategy with respect to clinical development. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements.
We have based these forward-looking statements largely on our current expectations and projections about future events.
Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from the impact of the COVID-19 pandemic on the national and global economy, on our collaboration partners, CROs, CMOs, and on our Company, including raw material and test animal shortages and other supply chain disruptions, the ability of our CROs to recruit volunteers for, and to proceed with, clinical trials, possible delays resulting from the lockdowns in Australia, potential delays related to the manufacturing of the drug for the study, the results of clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
Cocrystal Pharma Inc (COCP)
1.02 ? -0.03 (-2.86%)
Volume: 932,298 @09/22/21 7:43:30 PM EDT
Bid Ask Day's Range
1.01 1.03 1.0 - 1.0401
COCP Detailed Quote
COCP long term holders rewards are almost with the pipeline long in the works with cc-43244 and cdi-45205 as the covid compound is going to take off to the moon
COCP wake up call game time hope your suited up
Cocrystal Pharma Inc (COCP)
1.03 ? -0.04 (-3.74%)
Volume: 1,796,501 @08/13/21 7:57:15 PM EDT
Bid Ask Day's Range
1.02 1.03 1.02 - 1.07
COCP Detailed Quote
$COCP
Earnings Whisper
https://finance.yahoo.com/news/cocrystal-pharma-inc-cocp-report-190407433.html
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Cocrystal Pharma, Inc.
For Cocrystal Pharma, Inc.The Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination makes it difficult to conclusively predict that Cocrystal Pharma, Inc. Will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Cocrystal Pharma, Inc. Would post a loss of $0.04 per share when it actually produced a loss of $0.04, delivering no surprise.
The company has not been able to beat consensus EPS estimates in any of the last four quarters.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Cocrystal Pharma, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cocrystal Pharma, Inc. (COCP) : Free Stock Analysis Report
Every time you post the SP drops and there is massive shorting. Why is that?
COCP Yes. 1000% BARDA but now called APP in the works Antiviral Program For Pandemics otw
$COCP major move coming after all the pump and dumps and this time will stick!
Chart says - BREAK TO UPSIDE COMING !!
Dog, remember when this stock was a great flipper last year, the ebb and flow was ez money. I did keep a couple thousand shares because this will hit 4-5 bucks in the next year, but I’d love to see it jump around again.
Nice. Our bimonthly BARDA reminded lol
$COCP $10-15 same day APP is BARDA Antiviral Program For Pandemics and its otw and you will soon realize what a real investment is all about and not the daily noise
They’ve been jabbering about Barda forever. I’m not holding my breath. Just playing the pumps.
Why, is it not true? Figures....I got out at $2.40 so it doesn’t really matter but was hoping for 5 bucks. I check in every once in a while
Followers
|
103
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3011
|
Created
|
09/05/13
|
Type
|
Free
|
Moderators |
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses,
influenza viruses, and noroviruses.. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated
in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and
collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the
treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early discovery program
to identify and develop novel antivirals for the treatment of norovirus gastroenteritis.
Our proprietary structural biology, enzymology and medicinal chemistry expertise enable us to develop novel antiviral agents.
These technologies and our market-focused approach to drug discovery are designed to effectively create small molecule therapeutics
that are safe, effective and convenient to administer.
Our technology provides a 3-D structure of inhibitor complexes at near-atomic resolution and immediate insight to guide SAR.
This helps us identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement.
For any given viral disease, there are different subtypes of viruses that cause the disease. For example, there are six different subtypes of virus that cause hepatitis C.
In hepatitis C, these subtypes are termed "genotypes." Each hepatitis C genotype is common in some parts of the world and rare in others.
Our technology allows us to develop drug candidates that are effective against all subtypes of a given virus. The drug candidate is called broad spectrum.
Viral resistance is a major obstacle to developing effective antiviral therapies that target viral molecules. Viruses reproduce rapidly and in enormous quantities.
During reproduction, random variations in viral molecules called mutations spontaneously develop. If such a mutation occurs in a viral molecule that is targeted
by an antiviral therapy that therapy may no longer be effective against the mutated virus. These mutated or "resistant viruses" can freely infect and multiply even
in individuals who have received treatment. In some cases, resistant virus strains may even predominate. For example, in the 2009 swine influenza pandemic,
the predominant strain was resistant to the best available therapies.
To overcome this obstacle, we identify and target critical components of viral replication enzymes that are crucial to the function of the enzyme and sensitive to change.
Any mutation in these critical enzyme components is likely to inactivate the enzyme and, in turn render the virus incapable of replicating. We test the effectiveness of
our compounds against potential viral mutations and select compounds with the highest barrier to resistance.
Patients at risk for suffering from many viral infections have few effective antiviral treatments from which to choose. Furthermore, some available treatment options have characteristics that limit their market potential. They are either priced too high, poorly tolerated, inconvenient to administer, ineffective against some viral subtypes or prone to emergence of resistance.
Our technology is based on the work of our Chief Scientist and Chairman of our Scientific Advisory Board, Dr. Roger Kornberg, and Dr. Raymond Schinazi.
Dr. Kornberg was awarded the 2006 Nobel Prize for Chemistry for his work to visualize a replication enzyme called RNA polymerase in action.
Using techniques called protein cocrystallization and X-ray crystallography, Dr. Kornberg and his colleagues generated three dimensional pictures
similar to the one on the left of RNA being transcribed by an RNA polymerase.
Dr. Schinazi is a world-class expert in discovering novel nucleoside therapeutics. He co-founded several successful antiviral companies including
Triangle Pharmaceuticals Inc., Idenix Pharmaceuticals Inc. and Pharmasset, Inc.
We are leveraging both Dr. Kornberg's and Dr. Schinazi's expertise in these methods to identify and develop new antiviral compounds.
Using these methods, our scientists are able to:
Influenza is a severe respiratory illness caused by either the influenza A or B virus that results in outbreaks of disease mainly during the winter months.
Currently approved antiviral treatments for influenza are partially effective and prone to viral resistance. Strains of flu virus that are resistant to approved treatments,
osteltamivir (Tamiflu™), zanamavir (Relenza™) and Xofluza have appeared and in some cases are predominant.
For example, the predominant strain of the 2009 swine influenza pandemic was resistant to Tamiflu™.
These drugs target one of two viral proteins, hemagglutinin or neuraminidase, neither of which is highly conserved between viral strains.
In fact, different influenza virus strains such as H1N1 and H5N1 are named by their respective differences in hemagglutinin (H) and neuraminidase (N) proteins.
The ability of the influenza virus to produce viable variants of these two proteins is the key to its ability to develop resistance.
To learn more about influenza, please visit the information page at the Center for Disease Control and Prevention (CDC).
References: https://www.cdc.gov/flu/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |